Cellectis S.A. (CLLS)’s stock is trading at $2.48 at the moment marking a fall of -23.93% from the last session close. As of this writing, shares are priced at -59.08% less than their 52-week high of $6.06, and 35.52% over their 52-week low of $1.83. Based on the past 30-day period, the stock price is -41.31% below the high and +5.38% above the low.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
The 200-day Simple moving average is often placed more emphasis on by traders because of daily price changes. Investors will use the SMA-200 in different situations in trading activity as a key indicator to determine their support and resistance levels, and at the moment, CLLS’s SMA-200 is $2.87.
Further, it is important to consider CLLS stock ratios, particularly its price-to-sales ratio over the past twelve months, which stands at 6.81.
How does Cellectis S.A. (CLLS) stock rate among analysts? Buy, sell, or hold?
The key to trading is to concentrate on the future rather than on the past. During uncertain times, it can be hard to make decisions. The analysts who understand how a market works are usually the most accurate at forecasting its future. Currently, there are 5 brokerage firms that recommend the stock as a Moderate Buy. The ratings are commonly aggregated into a single number between 1 and 5. Buy or strong buy is scored 5, outperform is scored 4, hold is scored 3, underperform is scored 2 and strong sell is 1. Using a scale of 1-5, the current average recommendation is 3.80 in simple terms.
Cellectis S.A. (CLLS): Earnings History
If we examine Cellectis S.A.’s recent earnings history, in the last quarter ended on 9/29/2022, it posted adjusted earnings per share of -$0.63, beating the consensus of -$0.46. In other words, it beat the consensus by -$0.17, resulting in a -37.00% surprise. In the 3 months period before the previous quarter which was closed on 9/29/2022, the stock recorded adjusted earnings per share of -$0.63 in contrast with the Outlook of -$0.46. That was a difference of -$0.17 and a surprise of -37.00%.
Cellectis S.A. (CLLS): Earnings History
Most analysts expect public companies to report earnings and revenue in line with their projections, but sometimes these figures vary from what they actually expected. In the current quarter, the company had earnings predictions made by 3 different analysts, who are expecting earnings to fall in between the range of -0.52 and -1.02 with an average Earnings Estimate of -0.75 which is in contrast with the last year earnings estimate of -0.55 and also replicates -36.36% growth rate year over year.
Cellectis S.A. (NASDAQ: CLLS) Ownership Details
I will give a breakdown of the key shareholders in Cellectis S.A. (CLLS). Recent figures show that the company’s insiders hold 0.00% of shares. A total of 60 institutional investors hold shares in the company, making 23.25% of its stock and 23.25% of its float.
Sep 29, 2022, it was reported that the Company’s largest institutional holder is Long Focus Capital Management, LLC holding total of 2.68 million shares that make 5.89% of the company’s total number of shares and are currently priced at 6.66 million.
The securities firm Credit Suisse AG holds 1.44 million shares of CLLS, making it the second largest institutional shareholder. Taking this into account, the holding percentage comes to 3.16%, and the holding percentage of shares is valued at 3.57 million.
An overview of Cellectis S.A.’s technicals
In order to learn about trade movements and investor behavior, it is best to analyze the short, medium, and long term technical indicators along with the average volume of a stock. A 20-day average of the stock’s daily volume suggests Cellectis S.A. (CLLS) traded 166,659 shares per day, with a moving average of $3.23 and price change of -0.19. With the moving average of $2.59 and a price change of +0.22, about 138,320 shares changed hands on average over the past 50 days. Finally, CLLS’s 100-day average volume is 112,440 shares, alongside a moving average of $2.53 and a price change of -1.04.
Leave a Reply